TNFRSF17: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of TNFRSF17. The page also collects GeneMedi's different modalities and formats products for TNFRSF17 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TNFRSF17 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. [provided by RefSeq, Jul 2008]
Target ID | GM-T66693 |
Target Name | TNFRSF17 |
Gene ID | 608 |
Gene Official Name | TNFRSF17 |
Gene Alias | BCM, BCMA, CD269, TNFRSF13A |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target |
Pre-made TNFRSF17-specific INN-index biosimilar (antibody&conjugates)-motacabtagene lurevgedleucel, belantamab mafodotin, idecabtagene vicleucel, Elranatamab, Pavurutamab, Belantamab, Pacanalotamab, ciltacabtagene autoleucel, Alnuctamab, zevorcabtagene autoleucel, Teclistamab, orvacabtagene autoleucel
Anti-TNFRSF17 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pre-made anti-TNFRSF17 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-TNFRSF17 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TNFRSF17 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cat No. | Antibody Name | Format | Classified by tag | Order |
GM-Tg-hg-T66693-Ab | Anti-TNFRSF17 monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody | ![]() |